SEC Filing Summary: Aadi Bioscience, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aadi Bioscience, Inc. (not Whitehawk Therapeutics, Inc.) on December 7, 2022, reporting events occurring on December 6, 2022. The Company is a Delaware corporation with its principal executive offices in Pacific Palisades, California, and its common stock trades on The Nasdaq Stock Market under the symbol "AADI". The Company is classified as an emerging growth company.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a corporate governance report and does not provide clear values for financial performance metrics.
Material Changes
On December 6, 2022, the Board of Directors amended and restated the Company's bylaws, effective immediately. Key changes include:
- Revised procedures for director nominations and stockholder proposals, including a requirement for stockholders to provide evidence of compliance with Rule 14a-19 of the Securities Exchange Act of 1934 at least five business days before a meeting.
- Updates to stockholder meeting procedures to conform to recent amendments to the Delaware General Corporation Law (DGCL).
- Updates to provisions regarding directors, Board committees, and officers.
- Various ministerial changes and clarifications to align with current Delaware law.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the administrative update to the Company's bylaws.
Key Facts for Investor Verification
- Verify the specific text of the Amended and Restated Bylaws attached as Exhibit 3.1 to understand the full scope of governance changes.
- Confirm the impact of the new Rule 14a-19 compliance requirement on the timeline for stockholder nominations.
- Note that this filing is non-financial; investors should refer to the most recent 10-K or 10-Q for financial performance data.